Swiss drugmaker Novartis, on a deal-making spree this year, reported a gain in operating income of 6% as growth of its new drugs made up for stagnant revenue from established heart drug Entresto.
Third-quarter operating income, adjusted for special items, rose to $5.46 billion, slightly above consensus numbers cited by analysts of $5.4 billion.
